PL4005570T3 - Pridopidyna do zastosowania w leczeniu zespołu retta - Google Patents

Pridopidyna do zastosowania w leczeniu zespołu retta

Info

Publication number
PL4005570T3
PL4005570T3 PL22150695.9T PL22150695T PL4005570T3 PL 4005570 T3 PL4005570 T3 PL 4005570T3 PL 22150695 T PL22150695 T PL 22150695T PL 4005570 T3 PL4005570 T3 PL 4005570T3
Authority
PL
Poland
Prior art keywords
pridopidine
treatment
retts syndrome
retts
syndrome
Prior art date
Application number
PL22150695.9T
Other languages
English (en)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd. filed Critical Prilenia Neurotherapeutics Ltd.
Publication of PL4005570T3 publication Critical patent/PL4005570T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/451Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
PL22150695.9T 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta PL4005570T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16

Publications (1)

Publication Number Publication Date
PL4005570T3 true PL4005570T3 (pl) 2024-09-23

Family

ID=61619744

Family Applications (2)

Application Number Title Priority Date Filing Date
PL22150695.9T PL4005570T3 (pl) 2016-09-16 2017-09-15 Pridopidyna do zastosowania w leczeniu zespołu retta
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL17851614T PL3512506T3 (pl) 2016-09-16 2017-09-15 Zastosowanie pridopidyny w leczeniu zespołu retta

Country Status (13)

Country Link
EP (2) EP4005570B1 (pl)
JP (1) JP6977029B2 (pl)
CN (1) CN109982686A (pl)
AU (1) AU2017326013B2 (pl)
BR (1) BR112019005040A2 (pl)
CA (1) CA3036984C (pl)
DK (2) DK3512506T3 (pl)
ES (2) ES2986807T3 (pl)
HU (1) HUE058314T2 (pl)
IL (1) IL265342B2 (pl)
MX (1) MX388845B (pl)
PL (2) PL4005570T3 (pl)
WO (1) WO2018053280A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
EP4516356A3 (en) 2016-08-24 2025-05-14 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
MX2019002190A (es) 2016-08-24 2019-09-11 Prilenia Therapeutics Dev Ltd Uso de pridopidina para tratar distonías.
PL4005570T3 (pl) 2016-09-16 2024-09-23 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu retta
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
WO2020161707A1 (en) 2019-02-04 2020-08-13 Prilenia Neurotherapeutics Ltd. Low dose pridopidine for parkinson's disease and other diseases associated with parkinsonism
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
WO2006040155A1 (en) 2004-10-13 2006-04-20 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
EP2611759A1 (en) 2010-09-03 2013-07-10 Ivax International Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
TWI579272B (zh) * 2011-12-08 2017-04-21 梯瓦製藥國際有限責任公司 普多比啶(pridopidine)之氫溴酸鹽
JP6177875B2 (ja) 2012-04-04 2017-08-09 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーTeva Pharmaceuticals International GmbH 併用療法のための医薬組成物
SG11201509729YA (en) 2013-06-21 2015-12-30 Teva Pharmaceuticals Int Gmbh Use of high dose pridopidine for treating huntington's disease
EA201691454A1 (ru) * 2014-01-22 2017-01-30 Тева Фармасьютикалз Интернэшнл Гмбх Композиции придопидина модифицированного высвобождения
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
MX378579B (es) * 2015-02-25 2025-03-11 Prilenia Neurotherapeutics Ltd Uso de pridopidina para mejorar la funcion cognitiva y para tratamiento de enfermedad de alzheimer.
PL4005570T3 (pl) 2016-09-16 2024-09-23 Prilenia Neurotherapeutics Ltd. Pridopidyna do zastosowania w leczeniu zespołu retta

Also Published As

Publication number Publication date
DK4005570T3 (da) 2024-08-19
EP3512506A4 (en) 2020-05-27
JP2019532926A (ja) 2019-11-14
ES2909557T3 (es) 2022-05-09
CN109982686A (zh) 2019-07-05
HUE058314T2 (hu) 2022-07-28
AU2017326013B2 (en) 2020-12-24
BR112019005040A2 (pt) 2019-07-16
DK3512506T3 (da) 2022-04-19
IL265342B2 (en) 2023-06-01
PL3512506T3 (pl) 2022-05-30
WO2018053280A1 (en) 2018-03-22
EP4005570A1 (en) 2022-06-01
EP4005570B1 (en) 2024-05-15
JP6977029B2 (ja) 2021-12-08
EP3512506B1 (en) 2022-01-26
IL265342A (en) 2019-05-30
AU2017326013A1 (en) 2019-04-11
ES2986807T3 (es) 2024-11-12
EP3512506A1 (en) 2019-07-24
CA3036984A1 (en) 2018-03-22
MX2019003069A (es) 2019-09-02
MX388845B (es) 2025-03-20
CA3036984C (en) 2023-07-18

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL256056A (en) Ezh2 inhibitors for treating lymphoma
IL290993A (en) Methods of diagnosing and treating tourette syndrome
PL4005570T3 (pl) Pridopidyna do zastosowania w leczeniu zespołu retta
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
PL3212174T3 (pl) Sposoby leczenia zakażeń wirusem filoviridae
SI3785717T1 (sl) Postopki za zdravljenje okužb s Coronaviridae
IL252602B (en) Oral care compositions and methods of use
DK3227675T3 (da) Activin-actrii-antagonister og anvendelser til behandling af myelodysplastisk syndrom
PL3179991T3 (pl) Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
HRP20181661T1 (hr) Inhibitori jak1 za liječenje mijelodisplastičnih sindroma
DK3157527T3 (da) Ezh2-hæmmere til lymfombehandling
DK3142637T3 (da) Keratin treatment formulations and methods
LT3277842T (lt) Vėžio pacientų gydymo būdai farneziltransferazės inhibitoriais
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK3504187T3 (da) Anvendelse af pridopidin til behandling af funktionel tilbagegang
HUE037250T2 (hu) Duokarmicin ADC-k (antitest-hatóanyag konjugátumok) húgyhólyagrák kezelésében történõ alkalmazásra
EP3564335A4 (en) SURFACE TREATMENT AGENT
PL3200815T3 (pl) Sposoby i kompozycje do leczenia nowotworu
IL251759B (en) Compositions and methods for treating insomnia
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
HUE050944T2 (hu) Kezelési eljárás tradipitant alkalmazásával
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3302519T3 (da) Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom
EP3302207A4 (en) Surface treatment apparatuses and methods